| Primary information |
|---|
| ID | antitb_1195, |
| Name | 24915878 |
| N-Terminal modification | Boropentapeptide |
| C-Terminal Modification | AVKAA-B(OH)2 |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid |
| Length | Conjugated with Boronic acid |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium thermoresistible |
| In Vitro/ In vivo | Mycobacterium thermoresistible |
| Cell Line | Poorer inhibition than Pinanediol PD-protected Boropentapeptide |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1196, |
| Name | 24915878 |
| N-Terminal modification | Boropentapeptide |
| C-Terminal Modification | AVKAA-B(OH)2 |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid |
| Length | Conjugated with Boronic acid |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis |
| Cell Line | Poorer inhibition than Pinanediol PD-protected Boropentapeptide |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1197, |
| Name | 24915878 |
| N-Terminal modification | Boropentapeptide |
| C-Terminal Modification | AVKAA-B(OH)2 |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid |
| Length | Conjugated with Boronic acid |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis |
| Cell Line | Poorer inhibition than Pinanediol PD-protected Boropentapeptide |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |